NCT00573521CompletedNot Applicable
Risk Factors for Piperacillin/Tazobactam Resistance in Extended-Spectrum Beta-Lactamase (ESBL) Producing Organisms
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- University of Pittsburgh
- Enrollment
- 450
- Locations
- 1
- Primary Endpoint
- This research will help to identify risk factors for resistance to an antibiotic that is commonly used in the empiric treatment of critically ill patients.
Study Overview
Brief Summary
This research will be conducted to determine whether risk factors exist for piperacillin/tazobactam resistance in ESBL organisms.
Detailed Description
This is chart review at UPMC. NO human subject interaction will occur.
Study Design
- Study Type
- Observational
- Observational Model
- Other
- Time Perspective
- Retrospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Clinical information is collected by chart review of "case" and "control" patients.
- •A "case A" patient is defined as follows: One or more clinical cultures are positive for an ESBL producing bacteria and the organism is piperacillin/tazobactam resistant.
- •A "case B" patient is defined as follows: One or more clinical cultures are positive for an ESBL producing bacteria and the organism is piperacillin/tazobactam susceptible.
- •Additionally, 1 control patient in the hospital at the same time as the case patients will be randomly selected for each case and are not in either case group.
Exclusion Criteria
- •Patients < 18 years of age
Outcomes
Primary Outcomes
This research will help to identify risk factors for resistance to an antibiotic that is commonly used in the empiric treatment of critically ill patients.
Time Frame: 2 years
Secondary Outcomes
No secondary outcomes reported
Investigators
Brian Potoski
Assistant Professor
University of Pittsburgh
Study Sites (1)
Loading locations...
Similar Trials
Completed
Not Applicable
Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology UnitsGram-Positive Bacterial InfectionsEscherichia Coli InfectionsKlebsiella InfectionsNCT00167999Wyeth is now a wholly owned subsidiary of Pfizer200
Completed
Phase 4
Tazocin Intervention StudyBacterial InfectionsNCT00478855Wyeth is now a wholly owned subsidiary of Pfizer500
Completed
Not Applicable
Study Evaluating Piperacillin/Tazobactam in Complicated Urinary Infections.Urinary InfectionsNCT00195286Wyeth is now a wholly owned subsidiary of Pfizer180
Completed
Unknown
Identification of risk factors for post-operative nausea and vomitingAll surgical patients receiving general anesthesiaJPRN-UMIN000052565Chiba University Hospital1,200
Completed
Not Applicable
Digestive Colonisation by Highly Resistant Bacteria (CODBAHRE)Risk FactorNCT04085380Assistance Publique - Hôpitaux de Paris2,396